This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About MSD

MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, NJ, USA.

With offices in 140 countries, we aim to make a real difference with an innovative range of services and pharmaceutical products which promote and support health and wellbeing.

We produced the first tuberculosis (TB) vaccine in 1944, and continue to bring a number of pioneering medicines in areas such as heart disease and cancer. But it doesn’t stop there. As the healthcare needs of the world evolves, so does our pipeline- with the UK making forward investments in areas such as oncology, diabetes and antimicrobial resistance.

Our mission is simple: improving the health and well-being of humans and animals around the world.

Changes to our trading names and address

Please note that in 2021, MSD will be spinning off products from its women’s health, legacy brands, and biosimilars franchises into a new independent, publicly traded company known as Organon & Co.

Due to legal entity separation in advance of this spin off, we now have two UK registered businesses, MSD and Organon. Organon & Co. is a wholly owned subsidiary of Merck & Co., Inc. of Kenilworth, New Jersey, USA.

As a result of the future spin-off of Organon, as well as our head offices moving to London in early 2021, you will begin to see some changes to references to our products, contact details, materials and statements over the coming months.

“We try never to forget that medicine is for the people. It is not for the profits… We cannot rest until the way has been found with our help to bring our finest achievements to everyone.” George W. Merck, 1950

Manufacturing excellence in the UK

Our Cramlington pharmaceutical manufacturing facility commenced operations in 1975 and employs approximately 400 people today. The site has benefited from a number of major investment programmes over the years and is a centre of excellence for worldwide supply; and a global centre for stability testing.

Beyond The Pill Service

 

GB-NON-04118 | Date of Preparation: March 2021